MDGL
Madrigal Pharmaceuticals, Inc. (NASDAQ)
Healthcare — Biotechnology
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Strong Buy
1.4 / 5
14 analysts
$514.39
$-22.56 (-4.20%)
Target:
$678.71
(31.9%)
Sign in to add MDGL to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $11.86B |
| P/E Ratio (TTM) | - |
| Forward P/E | 41.55 |
| EPS (TTM) | $-13.48 |
| Dividend Yield | - |
| Profit Margin | -27.32% |
| Revenue Growth | 126.80% |
| ROE | -49.35% |
| Debt/Equity | 63.91 |
| Recommendation | Strong Buy 1.4 |
| Analyst Target | $678.71 |
| Analysts | 14 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 71.4 |
| Beta | -1.06 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $615.00 |
| 52-Week Low | $284.02 |
| 50-Day Avg | $508.68 |
| 200-Day Avg | $496.57 |
| Avg Volume | 328.1K |
| Volume | 303.7K |
Performance Analysis
BULLISHMDGL shows predominantly bullish signals based on its fundamentals and technicals.
~
Trading at 70% of its 52-week range.
-
RSI at 71.4 indicates overbought conditions — a pullback may be due.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
+
Strong revenue growth of 126.8% year-over-year.
-
Operating at a loss with -27.3% margin.
+
Wall Street consensus is "Strong Buy" from 14 analysts.
+
Average analyst target of $678.71 implies 31.9% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:19 UTC
Back to Screener Export Report